DMT1 Gene

📖 Wiki Page

gene1339 wordssynced 2026-04-02

DMT1 — Divalent Metal Transporter 1 (SLC11A2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DMT1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>DMT1 (SLC11A2)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>DCT1, NRAMP2, Divalent Cation Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12q14.2</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000104691</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6554</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>604187, 600042</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8IWU6</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>495 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~54 kDa</td>
</tr>
<tr>
<td class="label">Tissue/Cell Type</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Duodenum (enterocytes)</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Brain (neurons, glia)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Kidney (proximal tubule)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spleen</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="labe

...

DMT1 — Divalent Metal Transporter 1 (SLC11A2)

Overview

Mermaid diagram (expand to render)

DMT1 (Divalent Metal Transporter 1), also known as SLC11A2 (Solute Carrier Family 11 Member 2), is a transmembrane iron transporter essential for cellular iron uptake. It is encoded by the SLC11A2 gene located on chromosome 12q14.2 and functions as a proton-coupled metal ion transporter that imports ferrous iron (Fe2+) and other divalent metals into cells. DMT1 is expressed in multiple tissues, including the duodenum (where it absorbs dietary iron), brain, liver, and kidneys. The protein plays a critical role in systemic iron homeostasis and has been implicated in neurodegenerative diseases, particularly Parkinson's disease, where iron accumulation in the [substantia nigra](/brain-regions/substantia-nigra) is a hallmark feature. This page covers the gene's molecular function, protein structure, disease associations, expression patterns, and key research findings. [@ncbi][@uniprot]

Gene Information

Protein Structure and Domains

DMT1 is a member of the NRAMP (Natural Resistance-Associated Macrophage Protein) family and contains several structural features:

Transmembrane Domain Architecture

DMT1 contains 12 transmembrane helices that form the transport channel. The protein adopts a pseudo-symmetric fold typical of the NRAMP family, with two similar halves forming a central pore. The transmembrane domains are arranged to create a pathway for ion movement across the membrane.

Metal-Binding Sites

The interior of the transporter contains conserved residues that coordinate metal ion binding. Key binding sites include:

Aspartate and glutamate residues for Fe²⁺ coordination
Histidine residues for pH-sensitive binding
Methionine and serine residues for substrate specificity

Intracellular Domains

The N-terminal and C-terminal cytosolic domains contain regulatory motifs that control transporter activity through:

Post-translational modifications (phosphorylation)
Protein-protein interactions
Intracellular trafficking signals

GATE and Proline-Rich Regions

DMT1 contains a GATE (GABA Transporter) domain and proline-rich regions that may participate in protein interactions and trafficking regulation.

Molecular Mechanism of Action

Iron Transport

DMT1 functions as a proton-coupled divalent metal transporter:

Substrate Binding: DMT1 binds Fe²⁺ (ferrous iron) at the extracellular or luminal side of the membrane.

Proton Coupling: The transport is coupled to proton influx, utilizing the proton gradient to drive metal movement. This proton coupling allows DMT1 to function even when the membrane potential is not favorable.

Conformational Change: Binding triggers a conformational change that moves the metal ion through the channel.

Release: The metal is released into the cytosol, where it can be utilized or stored.

Substrate Specificity

DMT1 transports multiple divalent metals:

Iron (Fe²⁺): Primary substrate, essential for cellular metabolism
Manganese (Mn²⁺): Important for mitochondrial function and antioxidant enzymes
Copper (Cu²⁺): Required for enzyme function (e.g., cytochrome c oxidase)
Zinc (Zn²⁺): Involved in protein structure and enzyme catalysis
Cadmium (Cd²⁺): Toxic metal that can hijack DMT1 for entry
Cobalt (Co²⁺): Rarely transported

Regulation

DMT1 activity is regulated at multiple levels:

Transcriptional: Iron regulatory proteins (IRP) bind to IRE (iron-responsive element) sequences in the 3' UTR
Translational: Cellular iron status affects mRNA translation
Post-translational: Phosphorylation and protein interactions modulate activity
Trafficking: Subcellular localization controls transport activity

Expression Pattern

DMT1 exhibits broad tissue distribution with highest expression in absorptive and metabolic tissues:

In the brain, DMT1 is expressed in:

Dopaminergic neurons of the substantia nigra
[Microglia](/cell-types/microglia) Astrocytes
Endothelial cells of the blood-brain barrier

Disease Associations

Parkinson's Disease

DMT1 has emerged as a significant player in Parkinson's disease pathogenesis:

Iron Accumulation: DMT1-mediated iron uptake contributes to iron accumulation in the substantia nigra of PD patients. This iron accumulation leads to oxidative stress through Fenton chemistry, generating reactive oxygen species (ROS) that damage dopaminergic neurons.

DMT1 Overexpression: Studies show increased DMT1 expression in PD brains, particularly in the substantia nigra. This overexpression may be driven by iron dysregulation and create a feed-forward loop of iron accumulation.

Genetic Variants: Certain SLC11A2 polymorphisms have been associated with PD risk. Some variants may lead to increased transporter activity or altered regulation.

Neurotoxicity: Iron overload via DMT1 can:

Induce mitochondrial dysfunction
Activate microglia and neuroinflammation
Promote alpha-synuclein aggregation
Cause lipid peroxidation

Therapeutic Implications: DMT1 inhibitors are being explored as potential neuroprotective agents in PD. Iron chelation therapy has shown some promise in clinical trials.

Alzheimer's Disease

DMT1 contributes to AD pathogenesis through several mechanisms:

Brain Iron Dysregulation: Like PD, AD features iron accumulation in affected brain regions. DMT1 may contribute to this dysregulation.

Amyloid Precursor Protein (APP) Processing: Iron affects APP expression and processing. DMT1-mediated iron uptake may influence amyloid-beta production.

Oxidative Stress: Iron-catalyzed oxidative damage is a feature of AD pathology.

Neurodegeneration with Brain Iron Accumulation (NBIA)

While primarily associated with other genes (e.g., PANK2), DMT1 variants can contribute to iron accumulation phenotypes:

Rare SLC11A2 variants cause atypical NBIA
DMT1 dysfunction exacerbates brain iron accumulation

Iron Deficiency Anemia

DMT1 loss-of-function leads to impaired intestinal iron absorption:

SLC11A2 mutations cause iron deficiency anemia
Mouse models show microcytic, hypochromic anemia
The phenotype is more severe in combination with other iron transporter defects

Cancer

DMT1 expression is altered in certain cancers:

Some tumors upregulate DMT1 for increased iron uptake
DMT1 may support rapid proliferation through enhanced iron acquisition
May be a therapeutic target in iron-dependent cancers

Key Research Findings

Discovery and Characterization

Identified as a ferrous iron transporter (1990s)
Demonstrated proton-coupled transport mechanism
Shown to be essential for intestinal iron absorption
Murine knockout revealed anemia phenotype

Structural Studies

Cryo-EM structures of NRAMP family members solved
Transport mechanism characterized
Metal-binding sites identified

Physiological Studies

Role in systemic iron homeostasis defined
Brain expression patterns mapped
Regulation by iron status characterized

Animal Models

Mus musculus: Multiple mouse models have been generated:

Slc11a2 knockout: embryonic lethal or severe anemia
Conditional knockout in intestine: iron deficiency
Brain-specific knockout: altered neuronal iron homeostasis
mk (masked) mouse: natural DMT1 mutant with microcytic anemia

Danio rerio (Zebrafish): Used to study DMT1 function in development and iron transport.

Clinical Relevance

DMT1 is clinically relevant in several contexts:

PD Biomarker: DMT1 expression may serve as a marker of iron dysregulation in PD

Therapeutic Target: DMT1 inhibitors could reduce iron-mediated neurotoxicity

Iron Deficiency: Understanding DMT1 function informs treatment of iron deficiency

Drug Development: DMT1 modulators may have applications in neurodegeneration

Cross-links

[Iron Metabolism](/mechanisms/iron-metabolism) — Pathway page
[Parkinson's Disease](/diseases/parkinsons-disease) — Disease page
[Substantia Nigra](/brain-regions/substantia-nigra) — Brain region
[Oxidative Stress](/mechanisms/oxidative-stress) — Mechanism
[Divalent Metal Transporter](/proteins/dmt1-protein) — Protein page

External Links

[NCBI Gene: 6554](https://www.ncbi.nlm.nih.gov/gene/6554)
[UniProt: Q8IWU6](https://www.uniprot.org/uniprot/Q8IWU6)
[Ensembl: ENSG00000104691](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104691)
[GeneCards: SLC11A2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC11A2)
[OMIM: 604187](https://www.omim.org/entry/604187)

References

[Gunshin et al., Cloning and characterization of a mammalian proton-coupled metal-ion transporter (1997)](https://pubmed.ncbi.nlm.nih.gov/9171099/)

[Fleming et al., DMT1: a mammalian transporter for multiple metals (2000)](https://pubmed.ncbi.nlm.nih.gov/10831588/)

[Zhang et al., DMT1 and iron homeostasis in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19303751/)

[Wang et al., DMT1 expression in substantia nigra of PD patients (2010)](https://pubmed.ncbi.nlm.nih.gov/20153835/)

[Mao et al., DMT1 in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Jiang et al., Iron dysregulation in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[De Gregorio et al., DMT1 and neuroinflammation in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[Yun et al., DMT1 inhibitors as neuroprotective agents (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Meyer et al., Structure of NRAMP transporters (2019)](https://pubmed.ncbi.nlm.nih.gov/31789456/)

[Pantopoulos et al., Iron metabolism and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

Pathway Diagram

The following diagram shows the key molecular relationships involving DMT1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

DMT1 Gene

DMT1 — Divalent Metal Transporter 1 (SLC11A2)

DMT1 — Divalent Metal Transporter 1 (SLC11A2)

Overview

Gene Information

Protein Structure and Domains

Transmembrane Domain Architecture

Metal-Binding Sites

Intracellular Domains

GATE and Proline-Rich Regions

Molecular Mechanism of Action

Iron Transport

Substrate Specificity

Regulation

Expression Pattern

Disease Associations

Parkinson's Disease

Alzheimer's Disease

Neurodegeneration with Brain Iron Accumulation (NBIA)

Iron Deficiency Anemia

Cancer

Key Research Findings

Discovery and Characterization

Structural Studies

Physiological Studies

Animal Models

Clinical Relevance

Cross-links

See Also

External Links

References

Pathway Diagram